Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Latest News

Market cap$10B–$500B
All Over $50MOver $300MOver $2BOver $10B
All Under $1BUnder $10BUnder $100BUnder $500B
SectorsAll
Filter by sector
Thursday, October 15, 2026· 3770 stock ideas· 217 writers·
14,988 views· 7,128 clicks

October 2026 Random Ramblings

October 2026 market commentary covers SOLS’s cancelled merger, a hypothetical Starbucks-Chipotle deal, Russell 2000 weakness and AI premiums for Oura and home builders.

SBUX $103BCMG $38B
Yet Another Value Podcast 65 clicks

From X

@aleabitoreddit 1 click

Serenity on X

Clearly a macro related drop after CPI numbers came out today and further US rate hike anticipation. Since $KOSPI, $SPY, and Nikkei ended up plummeting. There's too many potential second/third order effects that's hard to map due if $CRWV goes down or frontier labs struggle (given contractual obligations). Rate hikes understandably amplifies a lot of those fears. But I do think everything getting sold off together presents opportunities. If $LITE has take/pay contracts + sold out until 2029 for lasers and is being financed by hyperscalers for 2031 demand. The demand visibility + financing (with counterparties like $MSFT or $AMZN) are too solid that I wouldn't bunch companies in the optical sector together (that already have cash on hand via ATMs or private placement). With a neocloud that requires billions in future toxic financing in high rate environments. I think markets will eventually distinguish nuances from actual profitability, financing, and long term demand sustainability rather than just treating everything as one "bubble".
@aleabitoreddit

Serenity on X

It's interesting to see Elon interacting with finance X accounts out of the blue. Then amplifying $CRWV financing concerns, Chinese memory flooding, to AI investors being gamblers recently. With $SPCX and $TSLA, I do think Elon is a visionary but from how it looks from the outside... Amplifying concerns about competitors does make their financing more difficult as a self-fulfilling prophecy. And multiple posts about Chinese memory flooding after calling Samsung/SK Hynix pricing extortion does harm these supplier valuations... The economic incentives of doing so probably benefits Tesla/SpaceX more in the long run, even if everything goes down together. There's merit to a lot of things (I've been voicing Coreweave concerns about debt interest + rate hikes for the longest time...). But much like high end memory flooding to nuances of "No crying in a Casino" when the $AVGO CEO comments were regarding OpenAI ARR datapoints... were missed. You can throw rocks at others when a glass house is propped up by passive index flows
@BrokenMoats

Broken Moats on X

Hottest trade in the past month.....retail stocks Seems odd with rates and oil and diesel moves over the same time frame. And these are not bounces from being oversold these are double digit moves in most cases to new highs while dpz struggled on their print this week, stocks like DKS collapsed around the time this trade started. Bifurcation in retail in recent weeks that seems to be favoring low quality. Something to watch for a reversal soon $KSS $FIGS $URBN $SHOP
@BrokenMoats 2 clicks

Broken Moats on X

Quickly back to very attractive levels to put back on short exposure on the software sector after the manic move in Q3 and digestion in September before the sudden crash up in the past 10 days..... AI wins software is in trouble - faster disruption more competition, pricing pressure AI trade is over, software is going to catch down as the market will tank and this won't sit that out (the are not cheap) Disruption and pricing is the tailwind, now valuation is too. Rates don't hurt either as up until recently these were considered long duration assets Recent results were status quo for most (no real acceleration) and pitch AI cohort growth as growing xx% but its not uplifting the total growth they are just changing what they charge for to show the street what it wants to hear) -- that phase is over, valuations are in many cases at year and multi year highs. SBC still a problem. Now comes renewals in the back of this year and thats where the issues will start to emerge on retention and pricing. An thats day 1 they will snowball overtime for the vast majority of these companies. Plenty of names to choose from: $PAYC $DOCU $TEAM $DDOG $PCTY $GDDY $RNG
@ParadisLabs 3 clicks

Paradis on X

An example that there are always trades in the market. $NAVN +12% in a ~couple weeks while sentiment & flows for semis/bottlenecks has fallen off. If anyone wants a Navan investment thesis: Navan is a corporate travel and expense platform. I believed that the market punished the stock (-22%) after Q2 earnings for no good reason. Plus, I also heard some pretty big investors bought the dip aggressively. It makes sense to follow the flows sometimes when fundamentals align. - Total GBV rose 45% to >$3B driven by new customers, ramping cohorts, and expansion of installed base. - Enterprise customers: Continued momentum in the enterprise market. - AI platform adoption: Over 50% of AI calls now run on Navan's proprietary models, with its AI support agent handling about 60% of customer interactions. Ultimately, investors were disappointed because they reported rising op. costs and expanded op. losses. But the market completely overlooked the fact that corporate traven demand has skyrocketed w/ business travel in the US generating $624B in GDP (Global Business Travel Association). Going forwards, I believe that enterprises will look for AI-native solutions that save them time and money while also resulting in better outcomes for the customer. From what I hear, Navan's AI is pretty sweet. ***I have taken profits to bolster my cash piles. Also, $IOT is flat over the same period.
@stockgutter 1 click

SG on X

I asked @grok to assess how the full results that $MRNA plans to release at ESMO that would strengthen or weaken the impression from top line results announced in August. The results are copied below. Seems reasonable to me at first glance (without having checked any of the data cited) -- anyone have a different view? ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ Items that could weaken (or further strengthen) the positive view include: - Magnitude of benefit: Hazard ratios (HRs), confidence intervals, absolute risk reductions, and landmark rates (e.g., 1- or 2-year RFS/DMFS). The earlier Phase 2b KEYNOTE-942 showed an RFS HR of ~0.51 (~49% relative risk reduction) and a DMFS HR of ~0.41 at 5 years. A substantially weaker Phase 3 effect (for example, HR closer to 0.75–0.85 with modest absolute benefit) could make the result look less compelling given the complexity, cost, and personalized manufacturing of the therapy. A comparable or stronger effect would reinforce the topline. - Statistical robustness and maturity: Width of confidence intervals, exact p-values, number of events, and median follow-up duration. Narrow intervals and a solid number of events support reliability; wide intervals, low event counts, or very short follow-up at the interim analysis could raise questions about reproducibility or durability. Subgroup consistency: Results by stage (IIB/IIC vs. III vs. IV), age, BRAF status, PD-L1 expression, geography, or other factors. Benefit concentrated in higher-risk stages or selected subgroups would narrow the practical population and commercial opportunity relative to a broadly consistent effect. Durability (Kaplan–Meier curves): Early separation that later plateaus or converges would suggest limited long-term impact. Sustained separation would support durability. - Overall survival signal: Any immature OS HR, death counts, or curve separation. An adverse or flat trend (while not decisive this early) could temper enthusiasm pending mature data. - Safety, tolerability, and feasibility details: Grade ≥3 adverse events, serious AEs, immune-related AEs, discontinuations, quality-of-life/patient-reported outcomes, and any manufacturing metrics (production success rate, turnaround time, or treatment delays). Higher toxicity, discontinuations, or practical barriers could offset efficacy gains. The topline noted consistency with prior experience and no new signals, but granular rates matter. - Stronger, consistent, durable efficacy with manageable safety and feasible delivery would solidify the positive assessment, support regulatory filings, and underpin commercial expectations. Marginal magnitude, inconsistency across key subgroups, limited durability, or meaningful safety/feasibility issues would lead to a more cautious view of clinical utility and value, even though the trial formally met its endpoints.

Investor Letters

All letters

Free Recaps of the best new stock ideas, delivered every morning.

Read past recaps

Lennar, Part One: The Story

Lennar grew from a Miami builder into one of America’s two largest homebuilders, controlling land largely through options and land banks…

LEN $17B
Latticework by MOI Global 7 clicks

Lennar, Part Two: The Deep Dive

Lennar’s second audio program examines the homebuilder’s business for professional investors and housing analysts.

LEN $17B
Latticework by MOI Global 9 clicks

Insider activity September 2026

Asian insider buying rose 19% to US$2.4 billion across 930 September transactions, led by Grab CEO Anthony Tan’s US$30 million purchase…

GRAB $12B
Asian Century Stocks 6 clicks

Expert Call | Corning

Corning’s NVIDIA-backed 10x fiber expansion, enterprise connector demand and carrier capacity plans frame its optical communications…

GLW $126B
P Equity Research 35 clicks
BAX · long

Baxter International INC

Baxter International sells IV solutions, infusion pumps and other essential medical products to hospitals, clinics and home-care providers.

BAX $13B
Value Investors Club

Top Rebound Stocks for Oct’26

Intuitive Surgical, down 32% from its January 2025 peak, faces slower US procedure growth and new robotic-surgery rivals despite $10.1…

ISRG $149B
Rebound Capital 1 click

Vertiv Holdings Co. (VRT)

Vertiv's 33% stock decline followed a 2026 forecast increase, despite a $15 billion backlog and rising AI data-center demand for power and…

VRT $91B
SixSigmaCapital: Navigating the Financial Markets

Have a source we’re missing? Send your pick

Recent recaps

Latest recap

Tuesday, October 13 64 stock ideas
  • Expert Call | Corning P Equity Research
  • Rollins (ROL), Verisure (VSURE), and the cost of standing still (Part 2, Verisure) Best Anchor Stocks
Read the recap

All recaps

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 107

YouTube 4

Blogs 17

Seeking Alpha 49 of 225

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

88 accounts
Nominate an account

Investor letters we follow

189 firms

Sectors

Ordered by how often our editor reaches for them.

Anything we’re missing?

Send us a pick